PMID- 30312750
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Linking)
VI  - 726
DP  - 2020 May 1
TI  - BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia.
PG  - 133870
LID - S0304-3940(18)30691-8 [pii]
LID - 10.1016/j.neulet.2018.10.015 [doi]
AB  - Antipsychotic drugs remain the mainstay of pharmacotherapy for schizophrenia. As 
      there are large individual variations in efficacy and side-effects of 
      antipsychotic drugs, there is a strong demand for personalized medication to 
      treat schizophrenia. Pharmacogenetic research into antipsychotic drugs has 
      examined a number of genetic variants and only a few polymorphisms have been 
      found which promise to be associated with the therapeutic efficacy and 
      side-effects of antipsychotic drugs. Brain-derived neurotrophic factor (BDNF) is 
      a neurotrophin that plays a major role in neurogenesis and neuroplasticity, and 
      in the modulation of several neurotransmitter systems including the dopaminergic 
      system involved in the pathophysiology of schizophrenia. This review focused on 
      the association between the BDNF gene Val66Met polymorphism and antipsychotic 
      drugs. The BDNF Val66Met polymorphism has been related to the pathophysiology of 
      schizophrenia, psychotic symptomatology, cognition, efficacy and side-effects of 
      antipsychotic drugs. The BDNF Val66Met variants could be a promising target for 
      antipsychotic medication options or developing next generation antipsychotic 
      drugs. However, some studies showed inconsistent results due to sample size, 
      ethnic differences and different antipsychotic drugs. Further studies will be 
      required in this area to confirm the effect of the BDNF Val66Met polymorphism in 
      the pathophysiology of schizophrenia and patients' response to antipsychotic 
      drugs, especially in a larger sample size and in different ethnic populations.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Han, Mei
AU  - Han M
AD  - Antipsychotic Research Laboratory, Illawarra Health and Medical Research 
      Institute, Wollongong, 2522, NSW, Australia; School of Medicine, University of 
      Wollongong, Wollongong, 2522, NSW, Australia.
FAU - Deng, Chao
AU  - Deng C
AD  - Antipsychotic Research Laboratory, Illawarra Health and Medical Research 
      Institute, Wollongong, 2522, NSW, Australia; School of Medicine, University of 
      Wollongong, Wollongong, 2522, NSW, Australia. Electronic address: 
      chao@uow.edu.au.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20181009
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Animals
MH  - Antipsychotic Agents/*administration & dosage/metabolism
MH  - Brain-Derived Neurotrophic Factor/*genetics/metabolism
MH  - Drug Delivery Systems/*methods/trends
MH  - Humans
MH  - Polymorphism, Genetic/genetics
MH  - Schizophrenia/*drug therapy/*genetics/metabolism
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antipsychotic drugs
OT  - Brain-derived neurotrophic factor
OT  - Genetic variants
OT  - Polymorphisms
OT  - Schizophrenia
EDAT- 2018/10/13 06:00
MHDA- 2021/04/20 06:00
CRDT- 2018/10/13 06:00
PHST- 2018/06/07 00:00 [received]
PHST- 2018/10/04 00:00 [revised]
PHST- 2018/10/08 00:00 [accepted]
PHST- 2018/10/13 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
PHST- 2018/10/13 06:00 [entrez]
AID - S0304-3940(18)30691-8 [pii]
AID - 10.1016/j.neulet.2018.10.015 [doi]
PST - ppublish
SO  - Neurosci Lett. 2020 May 1;726:133870. doi: 10.1016/j.neulet.2018.10.015. Epub 
      2018 Oct 9.